Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Iridex Corp (NASDAQ: IRIX)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nektar Therapeutics (NASDAQ: NKTR) and Iridex Corp (NASDAQ: IRIX) with bullish sentiments.

Nektar Therapeutics (NASDAQ: NKTR)

Roth Capital analyst Michael Higgins reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) yesterday and set a price target of $31. The company’s shares opened today at $19.22.

Higgins said:

“We expect Nektar to continue to look for other collaboration agreements with this asset going forward.”

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -15.6% and a 27.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Sucampo Pharmaceuticals, Juniper Pharmaceuticals, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $26.25, representing a 36.6% upside.

In a report issued on May 10, Aegis Capital also reiterated a Buy rating on the stock with a $27 price target.
Iridex Corp (NASDAQ: IRIX)

Roth Capital analyst Chris Lewis reiterated a Buy rating on Iridex Corp (NASDAQ: IRIX) today and set a price target of $13. The company’s shares opened today at $8.95, close to its 52-week low of $8.70.

Lewis said:

“We accompanied Iridex’s CEO and CFO for a series of investor meetings in the Midwest last week. We came away from these meetings with additional insight into the magnitude of the sales expansion transition period the company is working through and the company’s reaffirmed bullish long-term outlook for G6.”

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 4.9% and a 48.4% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Lemaitre Vascular.

Iridex Corp has an analyst consensus of Moderate Buy, with a price target consensus of $13.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.